These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 36729405

  • 1. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6.
    Ji J, Zhang Z, He X, Pan G, Li G, Lv J, Xu Y, Xie M, Feng J, Wang W, Liu B, Ma J, Wang X.
    Anticancer Drugs; 2023 Aug 01; 34(7):803-815. PubMed ID: 36729405
    [Abstract] [Full Text] [Related]

  • 2. WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6.
    Ji J, Liu W, Xu Y, Xu Z, Lv M, Feng J, Lv J, He X, Zhang Z, Xie M, Jing A, Wang X, Ma J, Liu B.
    Front Pharmacol; 2022 Aug 01; 13():1072194. PubMed ID: 36744210
    [Abstract] [Full Text] [Related]

  • 3. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T, Xiong Y, Wang Q, Chen F, Zeng Y, Yu X, Wang Y, Zhou F, Zhou Y.
    Artif Cells Nanomed Biotechnol; 2019 Dec 01; 47(1):4001-4011. PubMed ID: 31588803
    [Abstract] [Full Text] [Related]

  • 4. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y, Li T, Assani G, Ling H, Zhou Q, Zeng Y, Zhou F, Zhou Y.
    Biomed Pharmacother; 2019 Apr 01; 112():108602. PubMed ID: 30784916
    [Abstract] [Full Text] [Related]

  • 5. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN.
    Cell Oncol (Dordr); 2019 Oct 01; 42(5):705-715. PubMed ID: 31250364
    [Abstract] [Full Text] [Related]

  • 6. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
    Lee HJ, Lee WK, Kang CW, Ku CR, Cho YH, Lee EJ.
    Cancer Lett; 2018 Mar 28; 417():131-140. PubMed ID: 29306020
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells.
    Baghermanesh SS, Barati M, Hosseini A.
    PLoS One; 2024 Mar 28; 19(8):e0309289. PubMed ID: 39196911
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S, Sun X, Luo L, Yang Y, Guo Q, Tang S, Jiang Z, Li Y, Han J, Gan W, Yang F, Zhang X, Liu Y, Sun C, He J, Liu M, Zuo D, Zhu W, Wu Y.
    Biomed Pharmacother; 2022 Nov 28; 155():113537. PubMed ID: 36113258
    [Abstract] [Full Text] [Related]

  • 11. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.
    Chen F, Zhang Z, Yu Y, Liu Q, Pu F.
    Int J Oncol; 2020 Jul 28; 57(1):223-236. PubMed ID: 32377705
    [Abstract] [Full Text] [Related]

  • 12. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z, Li Z, Lai Y, Gao J, Shen L.
    J Transl Med; 2017 Jun 02; 15(1):127. PubMed ID: 28578693
    [Abstract] [Full Text] [Related]

  • 13. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
    Teo ZL, Versaci S, Dushyanthen S, Caramia F, Savas P, Mintoff CP, Zethoven M, Virassamy B, Luen SJ, McArthur GA, Phillips WA, Darcy PK, Loi S.
    Cancer Res; 2017 Nov 15; 77(22):6340-6352. PubMed ID: 28947417
    [Abstract] [Full Text] [Related]

  • 14. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
    Liu CY, Lau KY, Hsu CC, Chen JL, Lee CH, Huang TT, Chen YT, Huang CT, Lin PH, Tseng LM.
    PLoS One; 2017 Nov 15; 12(12):e0189007. PubMed ID: 29261702
    [Abstract] [Full Text] [Related]

  • 15. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer.
    Huang Y, Wu H, Li X.
    Cancer Cell Int; 2020 Nov 15; 20():501. PubMed ID: 33061853
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
    Chen D, Sun X, Zhang X, Cao J.
    Biomed Res Int; 2020 Nov 15; 2020():9525207. PubMed ID: 32626773
    [Abstract] [Full Text] [Related]

  • 17. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
    Aristizabal Prada ET, Nölting S, Spoettl G, Maurer J, Auernhammer CJ.
    Neuroendocrinology; 2018 Nov 15; 106(1):58-73. PubMed ID: 28226315
    [Abstract] [Full Text] [Related]

  • 18. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J.
    Breast Cancer; 2021 Jan 15; 28(1):206-215. PubMed ID: 32860163
    [Abstract] [Full Text] [Related]

  • 19. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
    Bortolozzi R, Mattiuzzo E, Trentin L, Accordi B, Basso G, Viola G.
    Biochem Pharmacol; 2018 Jul 15; 153():230-241. PubMed ID: 29408328
    [Abstract] [Full Text] [Related]

  • 20. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
    Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A.
    Invest New Drugs; 2014 Oct 15; 32(5):825-37. PubMed ID: 24919854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.